Compare Stocks

4 / 10
Try these comparisons:

Stock Comparison

RR vs BBOT vs BBIO vs BRBS

Revenue, margins, valuation, and 5-year total return — side by side.

Live fundamentals10-year financials5-year price chart
RR
Richtech Robotics Inc. Class B Common Stock

Industrial - Machinery

IndustrialsNASDAQ • US
Market Cap$467M
5Y Perf.+58.1%
BBOT
BridgeBio Oncology Therapeutics Inc.

Biotechnology

HealthcareNASDAQ • US
Market Cap$185M
5Y Perf.-26.1%
BBIO
BridgeBio Pharma, Inc.

Biotechnology

HealthcareNASDAQ • US
Market Cap$13.08B
5Y Perf.+97.3%
BRBS
Blue Ridge Bankshares, Inc.

Banks - Regional

Financial ServicesAMEX • US
Market Cap$320M
5Y Perf.+40.4%

RR vs BBOT vs BBIO vs BRBS — Key Financials

Market cap, revenue, margins, and valuation side-by-side.

Company Snapshot
RR logoRR
BBOT logoBBOT
BBIO logoBBIO
BRBS logoBRBS
IndustryIndustrial - MachineryBiotechnologyBiotechnologyBanks - Regional
Market Cap$467M$185M$13.08B$320M
Revenue (TTM)$5M$0.00$566M$151M
Net Income (TTM)$-12M$-134M$-726M$11M
Gross Margin55.8%95.1%63.5%
Operating Margin-5.2%-100.8%9.1%
Forward P/E31.8x
Total Debt$730K$3M$2.73B$179M
Cash & Equiv.$194M$374M$570M$116M

RR vs BBOT vs BBIO vs BRBSLong-Term Stock Performance

Price return indexed to 100 at period start. Dividends excluded.

RR
BBOT
BBIO
BRBS
StockFeb 24May 26Return
Richtech Robotics I… (RR)100158.1+58.1%
BridgeBio Oncology … (BBOT)10073.9-26.1%
BridgeBio Pharma, I… (BBIO)100197.3+97.3%
Blue Ridge Bankshar… (BRBS)100140.4+40.4%

Price return only. Dividends and distributions are not included.

Quick Verdict: RR vs BBOT vs BBIO vs BRBS

Each card shows where this stock fits in a portfolio — not just who wins on paper.

Bottom line: BRBS leads in 4 of 6 categories, making it the strongest pick for profitability and margin quality and capital preservation and lower volatility. BridgeBio Pharma, Inc. is the stronger pick specifically for growth and revenue expansion and recent price momentum and sentiment. This set spans 3 sectors — these stocks serve different portfolio roles, not just different price points.
RR
Richtech Robotics Inc. Class B Common Stock
The Specific-Use Pick

RR plays a supporting role in this comparison — it may shine differently against other peers.

Best for: industrials exposure
BBOT
BridgeBio Oncology Therapeutics Inc.
The Defensive Pick

BBOT is the clearest fit if your priority is sleep-well-at-night and defensive.

  • Lower volatility, beta 0.96, Low D/E 0.7%, current ratio 12.14x
  • Beta 0.96, current ratio 12.14x
Best for: sleep-well-at-night and defensive
BBIO
BridgeBio Pharma, Inc.
The Income Pick

BBIO is the #2 pick in this set and the best alternative if income & stability and growth exposure is your priority.

  • Dividend streak 0 yrs, beta 1.23
  • Rev growth 126.3%, EPS growth -31.6%, 3Y rev CAGR 86.3%
  • 144.8% 10Y total return vs BBOT's -22.9%
  • 126.3% revenue growth vs BBOT's -80.5%
Best for: income & stability and growth exposure
BRBS
Blue Ridge Bankshares, Inc.
The Banking Pick

BRBS carries the broadest edge in this set and is the clearest fit for quality and stability.

  • 7.1% margin vs RR's -249.5%
  • Beta 0.54 vs RR's 4.02
  • 6.1% yield; the other 3 pay no meaningful dividend
  • 0.4% ROA vs BBIO's -66.2%, ROIC 2.0% vs -5.2%
Best for: quality and stability
See the full category breakdown
CategoryWinnerWhy
GrowthBBIO logoBBIO126.3% revenue growth vs BBOT's -80.5%
Quality / MarginsBRBS logoBRBS7.1% margin vs RR's -249.5%
Stability / SafetyBRBS logoBRBSBeta 0.54 vs RR's 4.02
DividendsBRBS logoBRBS6.1% yield; the other 3 pay no meaningful dividend
Momentum (1Y)BBIO logoBBIO+88.3% vs BBOT's -27.6%
Efficiency (ROA)BRBS logoBRBS0.4% ROA vs BBIO's -66.2%, ROIC 2.0% vs -5.2%

RR vs BBOT vs BBIO vs BRBS — Revenue Breakdown by Segment

How each company's revenue is distributed across its business units

RRRichtech Robotics Inc. Class B Common Stock
FY 2025
Service
100.0%$1M
BBOTBridgeBio Oncology Therapeutics Inc.

Segment breakdown not available.

BBIOBridgeBio Pharma, Inc.
FY 2025
Product
72.2%$362M
License and Service
25.6%$128M
Royalty
2.3%$11M
BRBSBlue Ridge Bankshares, Inc.
FY 2020
Bank And Purchase Card Revenue
100.0%$1M

RR vs BBOT vs BBIO vs BRBS — Financial Metrics

Side-by-side numbers across 4 stocks — who leads on profitability, valuation, growth, and risk.

BEST OVERALLBRBSLAGGINGBBOT

Income & Cash Flow (Last 12 Months)

BRBS leads this category, winning 4 of 6 comparable metrics.

BBIO and BBOT operate at a comparable scale, with $566M and $0 in trailing revenue. BRBS is the more profitable business, keeping 7.1% of every revenue dollar as net income compared to RR's -2.5%. On growth, BBIO holds the edge at +54.8% YoY revenue growth, suggesting stronger near-term business momentum.

MetricRR logoRRRichtech Robotics…BBOT logoBBOTBridgeBio Oncolog…BBIO logoBBIOBridgeBio Pharma,…BRBS logoBRBSBlue Ridge Banksh…
RevenueTrailing 12 months$5M$0$566M$151M
EBITDAEarnings before interest/tax-$23M-$166M-$563M$15M
Net IncomeAfter-tax profit-$12M-$134M-$726M$11M
Free Cash FlowCash after capex-$10M-$95M-$454M$9M
Gross MarginGross profit ÷ Revenue+55.8%+95.1%+63.5%
Operating MarginEBIT ÷ Revenue-5.2%-100.8%+9.1%
Net MarginNet income ÷ Revenue-2.5%-128.2%+7.1%
FCF MarginFCF ÷ Revenue-2.1%-80.2%+2.5%
Rev. Growth (YoY)Latest quarter vs prior year-8.8%+54.8%
EPS Growth (YoY)Latest quarter vs prior year+100.0%-21.2%+4.5%+2.6%
BRBS leads this category, winning 4 of 6 comparable metrics.

Valuation Metrics

Evenly matched — RR and BBOT and BRBS each lead in 1 of 3 comparable metrics.
MetricRR logoRRRichtech Robotics…BBOT logoBBOTBridgeBio Oncolog…BBIO logoBBIOBridgeBio Pharma,…BRBS logoBRBSBlue Ridge Banksh…
Market CapShares × price$467M$185M$13.1B$320M
Enterprise ValueMkt cap + debt − cash$274M-$186M$15.2B$383M
Trailing P/EPrice ÷ TTM EPS-20.62x-1.83x-17.80x31.82x
Forward P/EPrice ÷ next-FY EPS est.
PEG RatioP/E ÷ EPS growth rate
EV / EBITDAEnterprise value multiple25.54x
Price / SalesMarket cap ÷ Revenue92.59x26.04x2.13x
Price / BookPrice ÷ Book value/share1.21x0.60x1.15x
Price / FCFMarket cap ÷ FCF85.53x
Evenly matched — RR and BBOT and BRBS each lead in 1 of 3 comparable metrics.

Profitability & Efficiency

BRBS leads this category, winning 6 of 9 comparable metrics.

BRBS delivers a 3.1% return on equity — every $100 of shareholder capital generates $3 in annual profit, vs $-66 for BBOT. RR carries lower financial leverage with a 0.00x debt-to-equity ratio, signaling a more conservative balance sheet compared to BRBS's 0.55x. On the Piotroski fundamental quality scale (0–9), RR scores 5/9 vs BBIO's 2/9, reflecting solid financial health.

MetricRR logoRRRichtech Robotics…BBOT logoBBOTBridgeBio Oncolog…BBIO logoBBIOBridgeBio Pharma,…BRBS logoBRBSBlue Ridge Banksh…
ROE (TTM)Return on equity-3.6%-65.5%+3.1%
ROA (TTM)Return on assets-3.5%-41.9%-66.2%+0.4%
ROICReturn on invested capital-25.7%-96.3%-5.2%+2.0%
ROCEReturn on capital employed-11.5%-48.0%-80.6%+0.5%
Piotroski ScoreFundamental quality 0–95425
Debt / EquityFinancial leverage0.00x0.01x0.55x
Net DebtTotal debt minus cash-$193M-$371M$2.2B$63M
Cash & Equiv.Liquid assets$194M$374M$570M$116M
Total DebtShort + long-term debt$730,000$3M$2.7B$179M
Interest CoverageEBIT ÷ Interest expense-158.47x-10.41x0.23x
BRBS leads this category, winning 6 of 9 comparable metrics.

Total Returns (Dividends Reinvested)

BBIO leads this category, winning 5 of 6 comparable metrics.

A $10,000 investment in BBIO five years ago would be worth $14,043 today (with dividends reinvested), compared to $3,234 for BRBS. Over the past 12 months, BBIO leads with a +88.3% total return vs BBOT's -27.6%. The 3-year compound annual growth rate (CAGR) favors BBIO at 70.9% vs RR's -20.1% — a key indicator of consistent wealth creation.

MetricRR logoRRRichtech Robotics…BBOT logoBBOTBridgeBio Oncolog…BBIO logoBBIOBridgeBio Pharma,…BRBS logoBRBSBlue Ridge Banksh…
YTD ReturnYear-to-date-23.0%-36.0%-13.8%-4.4%
1-Year ReturnPast 12 months+29.5%-27.6%+88.3%+24.6%
3-Year ReturnCumulative with dividends-49.0%-22.9%+398.9%-43.9%
5-Year ReturnCumulative with dividends-49.0%-22.9%+40.4%-67.7%
10-Year ReturnCumulative with dividends-49.0%-22.9%+144.8%-12.5%
CAGR (3Y)Annualised 3-year return-20.1%-8.3%+70.9%-17.5%
BBIO leads this category, winning 5 of 6 comparable metrics.

Risk & Volatility

Evenly matched — BBIO and BRBS each lead in 1 of 2 comparable metrics.

BRBS is the less volatile stock with a 0.54 beta — it tends to amplify market swings less than RR's 4.02 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. BBIO currently trades 79.4% from its 52-week high vs RR's 36.1% drawdown — a narrower gap to the peak suggests stronger recent price momentum.

MetricRR logoRRRichtech Robotics…BBOT logoBBOTBridgeBio Oncolog…BBIO logoBBIOBridgeBio Pharma,…BRBS logoBRBSBlue Ridge Banksh…
Beta (5Y)Sensitivity to S&P 5004.02x0.96x1.21x0.52x
52-Week HighHighest price in past year$7.43$14.87$84.94$4.79
52-Week LowLowest price in past year$1.71$7.63$31.77$3.25
% of 52W HighCurrent price vs 52-week peak+36.1%+52.9%+79.4%+73.1%
RSI (14)Momentum oscillator 0–10061.541.238.735.1
Avg Volume (50D)Average daily shares traded8.4M306K2.2M380K
Evenly matched — BBIO and BRBS each lead in 1 of 2 comparable metrics.

Analyst Outlook

Insufficient data to determine a leader in this category.

Analyst consensus: RR as "Buy", BBOT as "Buy", BBIO as "Buy". Consensus price targets imply 175.7% upside for BBOT (target: $22) vs 49.1% for BBIO (target: $101). BRBS is the only dividend payer here at 6.08% yield — a key consideration for income-focused portfolios.

MetricRR logoRRRichtech Robotics…BBOT logoBBOTBridgeBio Oncolog…BBIO logoBBIOBridgeBio Pharma,…BRBS logoBRBSBlue Ridge Banksh…
Analyst RatingConsensus buy/hold/sellBuyBuyBuy
Price TargetConsensus 12-month target$6.00$21.67$100.58
# AnalystsCovering analysts2326
Dividend YieldAnnual dividend ÷ price+6.1%
Dividend StreakConsecutive years of raises00
Dividend / ShareAnnual DPS$0.21
Buyback YieldShare repurchases ÷ mkt cap0.0%0.0%+0.4%+3.0%
Insufficient data to determine a leader in this category.
Key Takeaway

BRBS leads in 2 of 6 categories (Income & Cash Flow, Profitability & Efficiency). BBIO leads in 1 (Total Returns). 2 tied.

Best OverallBlue Ridge Bankshares, Inc. (BRBS)Leads 2 of 6 categories
Loading custom metrics...

RR vs BBOT vs BBIO vs BRBS: Key Questions Answered

8 questions · data-driven answers · updated daily

01

Is RR or BBOT or BBIO or BRBS a better buy right now?

For growth investors, BridgeBio Pharma, Inc.

(BBIO) is the stronger pick with 126. 3% revenue growth year-over-year, versus -13. 4% for Blue Ridge Bankshares, Inc. (BRBS). Blue Ridge Bankshares, Inc. (BRBS) offers the better valuation at 31. 8x trailing P/E, making it the more compelling value choice. Analysts rate Richtech Robotics Inc. Class B Common Stock (RR) a "Buy" — based on 2 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

02

Which is the better long-term investment — RR or BBOT or BBIO or BRBS?

Over the past 5 years, BridgeBio Pharma, Inc.

(BBIO) delivered a total return of +40. 4%, compared to -67. 7% for Blue Ridge Bankshares, Inc. (BRBS). Over 10 years, the gap is even starker: BBIO returned +144. 6% versus RR's -49. 0%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

03

Which is safer — RR or BBOT or BBIO or BRBS?

By beta (market sensitivity over 5 years), Blue Ridge Bankshares, Inc.

(BRBS) is the lower-risk stock at 0. 52β versus Richtech Robotics Inc. Class B Common Stock's 4. 02β — meaning RR is approximately 680% more volatile than BRBS relative to the S&P 500. On balance sheet safety, Richtech Robotics Inc. Class B Common Stock (RR) carries a lower debt/equity ratio of 0% versus 55% for Blue Ridge Bankshares, Inc. — giving it more financial flexibility in a downturn.

04

Which is growing faster — RR or BBOT or BBIO or BRBS?

By revenue growth (latest reported year), BridgeBio Pharma, Inc.

(BBIO) is pulling ahead at 126. 3% versus -13. 4% for Blue Ridge Bankshares, Inc. (BRBS). On earnings-per-share growth, the picture is similar: Blue Ridge Bankshares, Inc. grew EPS 135. 5% year-over-year, compared to -1034. 8% for BridgeBio Oncology Therapeutics Inc.. Over a 3-year CAGR, BBIO leads at 86. 3% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

05

Which has better profit margins — RR or BBOT or BBIO or BRBS?

Blue Ridge Bankshares, Inc.

(BRBS) is the more profitable company, earning 7. 1% net margin versus -312. 3% for Richtech Robotics Inc. Class B Common Stock — meaning it keeps 7. 1% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: BRBS leads at 9. 1% versus -355. 7% for RR. At the gross margin level — before operating expenses — BBIO leads at 94. 4%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

06

Which pays a better dividend — RR or BBOT or BBIO or BRBS?

In this comparison, BRBS (6.

1% yield) pays a dividend. RR, BBOT, BBIO do not pay a meaningful dividend and should not be held primarily for income.

07

Is RR or BBOT or BBIO or BRBS better for a retirement portfolio?

For long-horizon retirement investors, Blue Ridge Bankshares, Inc.

(BRBS) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0. 52), 6. 1% yield). Richtech Robotics Inc. Class B Common Stock (RR) carries a higher beta of 4. 02 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (BRBS: -13. 2%, RR: -49. 0%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

08

What are the main differences between RR and BBOT and BBIO and BRBS?

These companies operate in different sectors (RR (Industrials) and BBOT (Healthcare) and BBIO (Healthcare) and BRBS (Financial Services)), which means they face different economic cycles, regulatory environments, and macro sensitivities — making direct comparison nuanced.

In terms of investment character: RR is a small-cap high-growth stock; BBOT is a small-cap quality compounder stock; BBIO is a mid-cap high-growth stock; BRBS is a small-cap income-oriented stock. BRBS pays a dividend while RR, BBOT, BBIO do not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.

Find Stocks Like These

Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform all of them.

Stocks Like

RR

Quality Business

  • Sector: Industrials
  • Market Cap > $100B
  • Gross Margin > 33%
Run This Screen
Stocks Like

BBOT

Quality Business

  • Sector: Healthcare
  • Market Cap > $100B
Run This Screen
Stocks Like

BBIO

High-Growth Disruptor

  • Sector: Healthcare
  • Market Cap > $100B
  • Revenue Growth > 27%
  • Gross Margin > 57%
Run This Screen
Stocks Like

BRBS

Income & Dividend Stock

  • Sector: Financial Services
  • Market Cap > $100B
  • Net Margin > 5%
  • Dividend Yield > 2.4%
Run This Screen

You Might Also Compare

Based on how these companies actually compete and overlap — not just which sector they're filed under.